ICID 2020

20-23 February 2019
Kuala Lumpur, Malaysia

  • DNDi is a collaborative organization

PAHO secures significant price reductions for hepatitis C medicines

The Pan-American Health Organization (PAHO) has succeeded in reducing the price of expensive medicines that can cure people living with hepatitis C (HCV), according to an announcement made at its 57th Directing Council meeting. PAHO has negotiated prices of US$129 for 3 months of treatment from generic sources of sofosbuvir/daclatasvir. This significant a move could enable national programmes to scale up diagnosis and treatment and eliminate HCV as a public health problem.

Salam Today [25 July 2019]

“Kempen #MYmissingmillions Tingkat Kesedaran Saringan Awal Hepatitis C” – “The #MYmissingmillions campaign raises awareness about the importance of conducting early screening for hepatitis C”

Click here to read the article

Kempen Saringan Hepatitis C Seluruh Negara Anjuran Kementerian Kesihatan Malaysia

Kuala Lumpur – 17 Julai 2019

Kempen disokong oleh Drugs for Neglected Diseases initiative (DNDi) dan Foundation for Innovative New Diagnostics (FIND), bertujuan untuk mengesan pesakit yang menghidap HCV, iaitu sejenis penyakit yang senyap namun ianya boleh dirawat secara berkesan

Foundation for Innovative New Diagnostics’ (FIND) danDrugs for Neglected Diseases initiative’ (DNDi) sedang bekerjasama dengan Kementerian Kesihatan Malaysia (KKM) bagi melancarkan inisiatif terbesar di seluruh negara dalam usaha penyaringan virus hepatitis C (HCV).





การรณรงค์คัดกรองไวรัสตับอักเสบซีทั่วประเทศ โดยกระทรวงสาธารณสุขมาเลเซีย

กัวลาลัมเปอร์ – 17 กรกฎาคม 2562

สนับสนุนโดยองค์กรยารักษาโรคที่ถูกละเลยและมูลนิธิเพื่อการวินิจฉัยเชิงนวัตกรรมใหม่ การรณรงค์เพื่อค้นหา “ผู้สูญหายนับล้าน” สำหรับภัยเงียบจากโรคที่รักษาได้

มูลนิธิเพื่อการวินิจฉัยเชิงนวัตกรรมใหม่ (The Foundation for Innovative New Diagnostics -FIND) และองค์กรยาเพื่อรักษาโรคที่ถูกละเลย (Drugs for Neglected Diseases initiative – DNDi) ร่วมกับกระทรวงสาธารณสุขประเทศมาเลเซีย (MOH) เพื่อเปิดตัวโครงการคัดกรองไวรัสตับอักเสบซี (HCV) ที่ใหญ่ที่สุดในประเทศ

Nationwide hepatitis C screening campaign initiated by the Malaysian Ministry of Health

Kuala Lumpur – 17 July 2019
Supported by Drugs for Neglected Diseases initiative & Foundation for Innovative New Diagnostics, campaign seeks to find the “missing millions” for this silent but curable disease
FIND and DNDi are partnering with the Ministry of Health in Malaysia to launch the country’s biggest-ever screening initiative for the hepatitis C virus.

MedTrop 2019

Congress of the Brazilian Society of Tropical Medicine

28-31 July 2019
Belo Horizonte, Brazil

  • DNDi participating in several round tables and doing presentations on Chagas disease, leishmaniasis, and hepatitis C

R&D Portfolio Update February 2019: DNDi Hepatitis C programme

The first stage of the clinical trial in Malaysia and Thailand testing the ravidasvir/sofosbuvir combination showed excellent results in 301 chronically infected adults, as 97% of those enrolled were cured. Cure rates were notably high for the hardest-to-treat patients. Stage 2 of the study, to confirm the pangenotypic potential of the combination, has started.

4th National Hepatitis Conference 2019

7-8 March 2019
Kuala Lumpur, Malaysia

  • François Bompart, Director of Paediatric HIV/HCV Programmes – panel discussion on collaborative R&D model for hepatitis C
  • Isabelle Andrieux-Meyer, Head of Clinical Development Paediatric HIV/HCV Programmes – presentation of the HCV STORM Stage 1 results

Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission

by Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry JR, Cheinquer H, Dusheiko G, Feld JJ, Gore C, Griswold MG, Hamid S, Hellard ME, Hou J, Howell J, Jia J, Kravchenko N, Lazarus JV, Lemoine M, Lesi OA, Maistat L, McMahon BJ, Razavi H, Roberts TR, Simmons B, Sonderup MW, Spearman CW, Taylor BE, Thomas DL, Waked I, Ward JW, Wiktor SZ, on behalf of The Lancet Gastroenterology & Hepatology Commissioners.

The Lancet Gastroenterology & Hepatology, January 2019

Malaysia takes the lead on a public health approach to hepatitis C with new initiative to enhance diagnosis & treatment

New agreement between Clinical Research Malaysia & FIND on R&D for hepatitis C diagnostic tests continues an existing Malaysian partnership with DNDi for hepatitis C treatment

The Foundation for Innovative New Diagnostics (FIND) and Clinical Research Malaysia (CRM), both DNDi partners, recently signed a memorandum of understanding (MoU) to collaborate in the research and development of an innovative hepatitis C diagnostic testing strategy.